How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner

Rhanderson Cardoso, Roger S. Blumenthal, Stephen Kopecky, Francisco Lopez-Jimenez, Seth S. Martin

Research output: Contribution to journalReview article

Abstract

The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol was a landmark document guiding health care professionals around the globe on how to administer lipid-lowering therapies. Those guidelines were primarily focused on statin therapy benefit groups. The writing committee found insufficient evidence for specific low-density lipoprotein cholesterol (LDL-C) treatment targets. There have been many important updates in the lipid literature since the publication of that document. Most importantly, clinical trials have provided definitive evidence for the pivotal role of LDL-C in atherogenesis and the improvement in clinical outcomes by means of aggressive LDL-C reduction. Ezetimibe, evolocumab, and alirocumab treatment resulted in substantial reductions in major adverse cardiovascular outcomes. These data encourage a discussion on whether LDL-C targets are warranted in primary and/or secondary prevention, and if so, how low should those targets be. In order to answer such questions, the costs and safety of such therapies, as well as the safety of very low levels of LDL-C need to be addressed. This review discusses the relationship between LDL-C lowering and cardiovascular risk reduction, the efficacy, safety, and cost-effectiveness of high-intensity lipid-lowering therapies, and the recommendations from the most recent lipid guidelines.

Original languageEnglish (US)
JournalMayo Clinic proceedings
DOIs
StatePublished - Jan 1 2019

Fingerprint

LDL Cholesterol
Lipids
Costs and Cost Analysis
Guidelines
Safety
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risk Reduction Behavior
Primary Prevention
Group Psychotherapy
Secondary Prevention
Cost-Benefit Analysis
Publications
Atherosclerosis
Cholesterol
Clinical Trials
Delivery of Health Care

ASJC Scopus subject areas

  • Medicine(all)

Cite this

How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. / Cardoso, Rhanderson; Blumenthal, Roger S.; Kopecky, Stephen; Lopez-Jimenez, Francisco; Martin, Seth S.

In: Mayo Clinic proceedings, 01.01.2019.

Research output: Contribution to journalReview article

Cardoso, Rhanderson ; Blumenthal, Roger S. ; Kopecky, Stephen ; Lopez-Jimenez, Francisco ; Martin, Seth S. / How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner. In: Mayo Clinic proceedings. 2019.
@article{472eb61b58a746d48f583d44a7b535f9,
title = "How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner",
abstract = "The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol was a landmark document guiding health care professionals around the globe on how to administer lipid-lowering therapies. Those guidelines were primarily focused on statin therapy benefit groups. The writing committee found insufficient evidence for specific low-density lipoprotein cholesterol (LDL-C) treatment targets. There have been many important updates in the lipid literature since the publication of that document. Most importantly, clinical trials have provided definitive evidence for the pivotal role of LDL-C in atherogenesis and the improvement in clinical outcomes by means of aggressive LDL-C reduction. Ezetimibe, evolocumab, and alirocumab treatment resulted in substantial reductions in major adverse cardiovascular outcomes. These data encourage a discussion on whether LDL-C targets are warranted in primary and/or secondary prevention, and if so, how low should those targets be. In order to answer such questions, the costs and safety of such therapies, as well as the safety of very low levels of LDL-C need to be addressed. This review discusses the relationship between LDL-C lowering and cardiovascular risk reduction, the efficacy, safety, and cost-effectiveness of high-intensity lipid-lowering therapies, and the recommendations from the most recent lipid guidelines.",
author = "Rhanderson Cardoso and Blumenthal, {Roger S.} and Stephen Kopecky and Francisco Lopez-Jimenez and Martin, {Seth S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2018.08.011",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - How Low to Go With Lipid-Lowering Therapies in a Cost-effective and Prudent Manner

AU - Cardoso, Rhanderson

AU - Blumenthal, Roger S.

AU - Kopecky, Stephen

AU - Lopez-Jimenez, Francisco

AU - Martin, Seth S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol was a landmark document guiding health care professionals around the globe on how to administer lipid-lowering therapies. Those guidelines were primarily focused on statin therapy benefit groups. The writing committee found insufficient evidence for specific low-density lipoprotein cholesterol (LDL-C) treatment targets. There have been many important updates in the lipid literature since the publication of that document. Most importantly, clinical trials have provided definitive evidence for the pivotal role of LDL-C in atherogenesis and the improvement in clinical outcomes by means of aggressive LDL-C reduction. Ezetimibe, evolocumab, and alirocumab treatment resulted in substantial reductions in major adverse cardiovascular outcomes. These data encourage a discussion on whether LDL-C targets are warranted in primary and/or secondary prevention, and if so, how low should those targets be. In order to answer such questions, the costs and safety of such therapies, as well as the safety of very low levels of LDL-C need to be addressed. This review discusses the relationship between LDL-C lowering and cardiovascular risk reduction, the efficacy, safety, and cost-effectiveness of high-intensity lipid-lowering therapies, and the recommendations from the most recent lipid guidelines.

AB - The 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol was a landmark document guiding health care professionals around the globe on how to administer lipid-lowering therapies. Those guidelines were primarily focused on statin therapy benefit groups. The writing committee found insufficient evidence for specific low-density lipoprotein cholesterol (LDL-C) treatment targets. There have been many important updates in the lipid literature since the publication of that document. Most importantly, clinical trials have provided definitive evidence for the pivotal role of LDL-C in atherogenesis and the improvement in clinical outcomes by means of aggressive LDL-C reduction. Ezetimibe, evolocumab, and alirocumab treatment resulted in substantial reductions in major adverse cardiovascular outcomes. These data encourage a discussion on whether LDL-C targets are warranted in primary and/or secondary prevention, and if so, how low should those targets be. In order to answer such questions, the costs and safety of such therapies, as well as the safety of very low levels of LDL-C need to be addressed. This review discusses the relationship between LDL-C lowering and cardiovascular risk reduction, the efficacy, safety, and cost-effectiveness of high-intensity lipid-lowering therapies, and the recommendations from the most recent lipid guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85061029899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061029899&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.08.011

DO - 10.1016/j.mayocp.2018.08.011

M3 - Review article

C2 - 30737057

AN - SCOPUS:85061029899

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -